GRACE :: Lung Cancer

Lung Cancer

Denise Brock

Join Us! 2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know

Share

The Global Resource for Advancing Cancer Education (GRACE)
in partnership with Georgetown University Hospital
is pleased to present

2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know

Saturday, Nov. 18, 2017 | 1 – 3:30 pm; Leavey Center at Georgetown Hospital 
3800 Reservoir Road, NW, WASHINGTON, DC
 
View the Agenda
Register to Attend the Forum Live or via the Live Webcast
Suggested donation $15

 

 

 

How does immunotherapy work? Presented by Alex Spira, M.D., Ph.D., F.A.C.P. Virginia Cancer Specialists


 

 

Who should get immunotherapy for lung cancer? Presented by Benjamin Levy, MD Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital


 

 

What are the side effects? Presented by Stephen Liu, MD Lombardi Cancer Center, Georgetown University Hospital


 

 

 

Navigating clinical trials? Panel discussion


 

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

 


Denise Brock

Targeted Therapies in Lung Cancer Patient Forum 2017 – Presentations and Handouts

Share

Videos from the webcast Targeted Therapies Patient Forum 2017 are available for viewing, and for those who prefer to read the material, GRACE has made all speaker presentations and handouts available.  We have also included links to helpful social media and patient groups.  

Again, huge thanks to all of the faculty who spent their Saturday in Cleveland with our community, and thanks also to those organizations who sponsored this event – Astra Zeneca, Takeda, Boehringer Ingelheim, Ignyta, Novartis, Genentech, Caris, and Guardant Health.  

We started the day out with a warm welcome from our Forum Chair – Dr. Nathan Pennell.  For the full agenda, faculty list, presentations, and videos from the webcast, please visit the ‘webcast details’ page, available via this link.  For those who would like to view the presentations from the Targeted Therapies Patient Forum in Cleveland, please view and download all presentations and handouts here, or continue on for a list of what is available.   

The morning sessions kicked off with a warm welcome from Dr. Pennell.  

General Session
 
The Many Faces of Progression
Dr. Nathan Pennell, Cleveland Clinic Cancer Center  
Pennell – The Many Faces of Progression
 
The Role of Local Therapy
Dr. Shirish Gadgeel, Michigan Medicine, University of Michigan  
Gadgeel – Local Therapy  
 
Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope Comprehensive Cancer Center 
Reckamp – Biopsy and Re-biopsy
 
The Question of Clinical Trials
Dr. Alice Shaw, Massachusetts General Hospital
Shaw – Question of Clinical Trials
 
The Crossroads:
Local Therapy, Chemo, Targeted  Therapy, or Immunotherapy?
Panel Discussion with Drs. Pennell,  Gadgeel, Reckamp, and Shaw, and patients John Cherol (EGFR), Matt  Hiznay (ALK), and Sara Whitlock (RET), Moderator: Dr. H. (Jack) West
 
After lunch the breakout discussions continued: 
 
ALK/ROS1
Dr. Alice Shaw, Dr. Shirish Gadgeel, and Matt Hiznay, ALK patient
Shaw ALK/ROS1 Breakout  
Gadgeel – ALK Breakout
Hiznay ALK Breakout 
ROS1ders Information
 
ALK-positive NSCLC: ALK Positive
“ALK Positive” on Facebook (closed group): https://www.facebook.com/groups/ALKPositive/ 
“ALK Positive Outreach” on Facebook (public group): https://www.facebook.com/groups/ALKPositiveOR/
 
ROS1-positive cancer (any cancer):  The ROS1ders
“ROS1 Positive (ROS1+) Cancer” on Facebook (private group):  https://www.facebook.com/groups/ROS1cancer/
“ROS1 Cancer Research Forum” on Facebook (public community): https://www.facebook.com/ROS1CancerResearchForum/
“The ROS1ders” website: http://ros1cancer.com
ROS1ders Information
 
EGFR
Dr. Nathan Pennell, Dr. H. (Jack) West, and John Cherol, EGFR patient
West – EGFR Acquired Resistance  
Pennell – EGFR Initial Treatment
 
EGFR-positive NSCLC
“LUNGevity EGFR Group” on Facebook (closed group): https://www.facebook.com/groups/EGFRlung/
EGFR-positive patients who have developed resistance to at least one TKI
EGFR Resisters Lung Cancer Patient Group” on Facebook: https://www.facebook.com/groups/1992981107603006/
EGFR-positive Exon 20 insertion cancer (any cancer)
“Exon20 Group” website http://www.exon20group.org/
 
MET/RET/BRAF
Dr. Karen Reckamp, Dr. Vamsidhar  Velcheti, and Sara Whitlock, RET patient 
Reckamp – MET-RET-BRAF breakout
Velceti – MET RET Breakout
 
RET-positive NSCLC
“LUNGevity RET Group” on Facebook: https://www.facebook.com/groups/1230457690298084/
 
The day concluded with the afternoon general session: 
 
General Session
 
Managing the Cost of Cancer Care
Dr. James P. Stevenson, Cleveland Clinic Cancer Center
Stevenson -Managing the Cost of Cancer Care
 
Patient to Patient Mentoring
Kathryn Sefcek, MHA, 4th Angel Mentoring Program  
4th Angel Mentoring Program Information
4th Angel Mentoring Program
 
Caveat Emptor: Assessing Cancer Information from Sources of  Varying Quality  
Dr. H. (Jack) West, Swedish Cancer Institute & Founder of  cancerGRACE, and Janet Freeman-Daily, ROS1 patient,  #LCSM Twitter Chat co- moderator, Cure  Today contributor, blogger.
West – Caveat Emptor: Assessing Cancer Information from Sources of Varying Quality
Find Trusted Online Info About Lung Cancer 

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

 


Denise Brock

Targeted Therapies in Lung Cancer Patient Forum 2017 – It’s a Wrap!

Share

 

On Saturday, September 16, 2017, patients, caregivers, family members and friends joined GRACE in Cleveland at the Taussig Cancer Center for a full day of discussion on Targeted Therapies in Lung Cancer.  We are thrilled that people joined us for this amazing and informative day.  Huge thanks to all of the faculty who spent their Saturday in Cleveland with our community, and thanks also to those organizations who sponsored this event – Astra Zeneca, Takeda, Boehringer Ingelheim, Ignyta, Novartis, Genentech, Caris, and Guardant Health.  

 

We started the day out with a warm welcome from our Forum Chair – Dr. Nathan Pennell.  For the full agenda, faculty list, presentations, and videos from the webcast, please visit the ‘webcast details’ page, available via this link.     

  Brain Power

The morning sessions continued:

The Many Faces of Progression
 Dr. Nathan Pennell
 Cleveland Clinic Cancer Center
The Role of Local Therapy
 Dr. Shirish Gadgeel
 Michigan Medicine, University of Michigan
 Biopsies & Re-biopsies
 Dr. Karen Reckamp
 City of Hope Comprehensive Cancer Center 
The Question of Clinical Trials
 Dr. Alice Shaw
 Massachusetts General Hospital
 The Crossroads:
 Local Therapy, Chemo, Targeted  Therapy, or Immunotherapy?
 Panel Discussion with Drs. Pennell,  Gadgeel, Reckamp, and Shaw,
 and patients John Cherol (EGFR), Matt  Hiznay (ALK),
 and Sara Whitlock (RET).
 Moderator: Dr. H. (Jack) West 
 
 
 
Lunch was an opportunity to have further discussion with the faculty.  Cleveland Clinic Cancer Center graciously allowed us to set up lunch on the 1st floor in their beautiful new facility.

 
 
 
 
After lunch the breakout discussions continued: 
 
ALK/ROS1
 Dr. Alice Shaw, Dr. Shirish Gadgeel,
 and Matt Hiznay, ALK patient
 EGFR
 Dr. Nathan Pennell, Dr. H. (Jack) West,
 and John Cherol, EGFR patient
 MET/RET/BRAF
 Dr. Karen Reckamp, Dr. Vamsidhar  Velcheti, and Sara Whitlock, RET patient 
 
The day concluded with the afternoon general session: 
Managing the Cost of Cancer Care
 Dr. James P. Stevenson
 Cleveland Clinic Cancer Center
 Patient to Patient Mentoring
 Kathryn Sefcek, MHA
 4th Angel Mentoring Program
 Caveat Emptor: Assessing Cancer Information from Sources of  Varying Quality  
 Dr. H. (Jack) West
 Swedish Cancer Institute & Founder of  cancerGRACE
 and Janet Freeman-Daily, ROS1 patient,  #LCSM Twitter Chat co- moderator, Cure  Today contributor, blogger
 

Please click here to visit the Targeted Therapies in Lung Cancer Webcast page for viewing the videos in full!  (Please note, we will be editing the videos to cut them down – they are in raw format at this time).

 

 

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

 


Denise Brock

ASCO 2017 – Lung Cancer – What is the role for Immunotherapy in Relapsed Small Cell Lung Cancer after ASCO 2017?

Share
H. Jack West, MD
Medical Director
Thoracic Oncology Program Swedish Cancer Institute
President & CEO, GRACE
Matthew Gubens, MD
Thoracic Oncologist
Thoracic Surgery and Oncology Clinic
UCSF Helen Diller Family Comprehensive Cancer Center
Jyoti D. Patel, MD
Director Thoracic Oncology
University of Chicago Medicine

 

Drs. H. Jack West, Medical Director of the Thoracic Oncology Program at Swedish Cancer Institute in Seattle, Washington and President and CEO of GRACE, Matthew Gubens, Thoracic Oncologist at the Thoracic Surgery and Oncology Clinic of the UCSF Helen Diller Family Comprehensive Center in San Francisco, California, and Jyoti Patel, Director of Thoracic Oncology at University of Chicago Medicine gathered post meeting to discuss new information from ASCO 2017 regarding lung cancer.   In this roundtable video, the doctors discuss What is the role for Immunotherapy in Relapsed Small Cell Lung Cancer after ASCO 2017?



 

 Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

  
   
                   

 


Denise Brock

ASCO 2017 – Lung Cancer – Emerging Options for Malignant Pleural Mesothelioma

Share
H. Jack West, MD
Medical Director
Thoracic Oncology Program Swedish Cancer Institute
President & CEO, GRACE
Matthew Gubens, MD
Thoracic Oncologist
Thoracic Surgery and Oncology Clinic
UCSF Helen Diller Family Comprehensive Cancer Center
Jyoti D. Patel, MD
Director Thoracic Oncology
University of Chicago Medicine

 

Drs. H. Jack West, Medical Director of the Thoracic Oncology Program at Swedish Cancer Institute in Seattle, Washington and President and CEO of GRACE, Matthew Gubens, Thoracic Oncologist at the Thoracic Surgery and Oncology Clinic of the UCSF Helen Diller Family Comprehensive Center in San Francisco, California, and Jyoti Patel, Director of Thoracic Oncology at University of Chicago Medicine gathered post meeting to discuss new information from ASCO 2017 regarding lung cancer.   In this roundtable video, the doctors discuss Emerging Options for Malignant Pleural Mesothelioma.



 

 Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

  
   
                   

 


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243